Sentences with phrase «effects of the programs on»

«Premier Christy Clark needs to honour her commitment to put B.C. workers first by reviewing the effect of this program on B.C.»

Today, after analyzing the effect of the program on 105,351 women included in the study, the researchers conclude that, in addition to reducing the number of medically unjustified caesareans, the program has made it possible to save money.

However, the effects of these programs on the pool of funded NIH grants have not been reported.

Two recent experimental evaluations of the Louisiana Scholarship Program found negative effects of the program on student test scores but one study was limited to just a single year of outcome data and the second one (which I am leading) has only analyzed two years of outcome data so far.

We also examine the effects of the program on six - year graduation rates.

While the jury is still out on the effects of these programs on student test scores, there is significant evidence that they positively influence how far students continue in their schooling.

These profiles may be an important resource for those LEAs seeking to apply to the competition, as the profiles chronicle the history of how schools and districts started their blended - learning programs, the effect of these programs on student achievement, the blended - learning models they use, and the software or Internet tools that power these programs.

We found little evidence that the Choice program increased the test scores of participating students, though our final analysis revealed a positive effect of the program on reading scores when combined with high stakes testing.

At the same time, these evaluations also detected large positive effects of the programs on high school graduation.

It focuses on the effects of the program on students, staff, and schools.

The second is a study of the effects of the program on students» ideas about thinking and learning in general.

The first is a study of the effect of the program on students» and teachers» ideas about art.

This report discusses the effect of the Program on the aesthetic and critical thinking of participating students, as well as on the aesthetic thinking of participating teachers.

We find robust positive effects of each program on third - grade test scores in both reading and math.

We'd like to know, for instance, more about the effects of the program on post-secondary outcomes — similar to what has been done in the charter sector.

# 3: I'm super excited to announce that the KCP is partnering with the Oakland Unified School District on a project to research the effects of the program on student reading.

Also, understand the effect of their program on your credit record.

The effect of home visiting programs on mothers» life - course (subsequent pregnancies, education, employment, and use of welfare) is disappointing overall.10 In the trial of the nurse home visitor program described above, there were enduring effects of the program 15 years after birth of the first child on maternal life - course outcomes (e.g., interpregnancy intervals, use of welfare, behavioural problems due to women's use of drugs and alcohol, and arrests among women who were low - income and unmarried at registration).21 The effects of this program on maternal life - course have been replicated in separate trials with urban African - Americans20, 23,24 and with Hispanics.18

The effect of the program on arrests was not limited to any specific type of crime, although property crimes were more frequent and, therefore, accounted for a larger portion of the program effect on arrests overall.

The impact of the full program (prenatal and infancy home visitation) on children's use of alcohol and number of sexual partners is important because recent evidence indicates that alcohol use prior to age 15 years multiplies the risk of alcoholism in adulthood26 and multiple partners increase the risk for sexually transmitted diseases, including human immunodeficiency virus infection.27, 28 The effect of the program on alcohol use is consistent with greater alcohol consumption observed among adult rhesus monkeys who experienced aberrant rearing.29 These findings must be tempered, however, with an acknowledgment of their limitations.

Assess the effects of the programs on child and parent outcomes, including prenatal, maternal, and newborn health; child health and development; parenting skills; school readiness and academic achievement; crime and domestic violence; family economic self - sufficiency; and referrals and service coordination

Statistical analysis also indicated direct effects of the program on school readiness, suggesting that parenting practices had changed.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

«The good thing is that it's not toxic to humans and has been shown to not have any adverse effects on human health,» said Gubler, a professor emeritus at Duke University and a former head of the CDC's dengue program.

As such, we can not fully evaluate claims to the cost of the program or the effect it will have on employment.

Just examining a person's hourly wage does not consider the effects of taxation, social programs or tax credits on their after - tax income.

Jon Levs, author of All in: How Our Work - First Culture Fails Dads, Families, and Businesses — And How We Can Fix It Together, studied the effect of paid leave in California and New Jersey, which have paid family leave programs, and found that the majority of businesses reported that their state's paid leave programs had either no effect or a positive effect on their business.

The surprise move silenced critics of the program (at least temporarily), incensed the legions of businesses who'd come to rely on it and, perhaps most importantly, told the world that Kenney — who's only been helming the prestigious jobs portfolio since July 2013 — is a man capable of enacting changes that have a massive effect on the 1.1 million employers under his jurisdiction.

Concerns about such a knock - on effect on Viacom of the decline in traditional cable TV subscriptions deepened last quarter, when Charter Communications Inc moved five of its flagship networks to its most expensive programming tier, a move that will likely result in lower affiliate revenue for Viacom.

There isn't much data on the specific effects of AT&T and Verizon's paid - for zero - rating programs, but generally speaking, users seem more likely to consume a given service if it does not count against their data caps.

He said the latest and toughest sanctions resolutions against North Korea «are working, having an effect on the situation... on the capacity of the regime to obtain hard currency because to go along with the military programs or missile or nuclear (programs) you need money, and that's the objective.»

It may have to do with Addyi's high pricing (on par with Viagra at $ 26 per pill without an assistance program), its daily intake requirement (unlike Viagra, it adds up to $ 780 per month), its potentially deleterious side effects (low blood pressure and fainting), its restrictions on alcohol consumption (abstinence vs. large quantities not recommended for Viagra patients), a 10 % efficacy rate (whereas Viagra works 50 % of the time compared to a placebo, according to a recent study), and its subtle neurotransmitter - targeting mechanism (contrast that to the obvious hydraulics of Viagra).

Steib has turned his experience — including but not limited to the effect of stress at work — into a blog called The Career Manifesto, as well as into a workshop he hosts at XO Group, which includes a Personal Development Program and Lunch & Learn series, where he shares tips and advice on organization, management, productivity, and any other issues employees would like to explore.

«The second, less understood but far more sinister effect of these classified programs, is that they effectively create «permanent records» of our daily activities, even in the absence of any wrongdoing on our part,» Snowden wrote.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

In developing the National OCS Program, which has also been known as a Five Year Program, the Secretary is required to achieve an appropriate balance among the potential for environmental impacts, for discovery of oil and gas, and for adverse effects on the coastal zone.

He said that the revenue it draws — and «the addiction it creates» — has caused broadcasters to lose sight of its negative effect on Canadian programming, which is often shunted to undesirable timeslots or secondary channels to accommodate the «scheduling whims» of U.S. networks.

Moreover, the company made retroactive payments to its executives for about two - thirds of the income they lost while the program was in effect, on the theory that its stock price in 1981 was about two - thirds of its 1979 price.

Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions, including with respect to the Merger; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation in government - sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits of the Merger as a condition to obtaining regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration of the businesses of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion of management's attention from ongoing business operations and opportunities during the pendency of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability of financing, including relating to the proposed Merger; effects on the businesses as a result of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.express-scripts.com.

We also promote tax simplification; identify and fight the creep of specialized deductions; conduct, synthesize and curate research on the effect of globalization and technological trends on the US economy; and encourage growth advocates to focus more attention on cutting harmful regulations and increasing program efficiency than attempts to radically pare down social spending.

A Congress or Administration that wants to support broader employee share ownership and profit sharing in economic rewards could develop a checklist on any major program or legislation that is proposed to examine its likely effects on, and capacity to increase, financial participation and capital ownership and access to income on capital of employees and citizens in our economy.

The Enterprise Compensation Committee discharges the board of directors» responsibilities relating to the compensation of our executives and directors; reviews and discusses with management the Compensation Discussion and Analysis and performs other reviews and analyses and makes additional disclosures as required of compensation committees by the rules of the SEC or applicable exchange listing requirements; provides general oversight of our compensation structure, including our equity compensation plans and benefits programs, and confirms that these plans and programs do not encourage risk taking that is reasonably likely to have a material adverse effect on Hewlett Packard Enterprise; reviews and provides guidance on our human resources programs; and retains and approves the retention terms of the Enterprise Compensation Committee's independent compensation consultants and other independent compensation experts.

WASHINGTON — Most business economists believe the Federal Reserve's controversial bond - buying stimulus program has helped boost the recovery, but differ on the effects of the healthcare reform law and other policies by President Obama and Congress, according to survey results released Monday.

The right environment — corporate culture — can have an effect on the outcome of your employee advocacy program.

He also discussed the large - scale asset purchases of the Fed's quantitative easing program, casting doubt on much of the literature of the day — which tended to find positive, but limited effects of such purchases on reducing bond yields.

The recent geopolitical reports have had little effect on markets as end of year programs are set to buy mode.

While Japan's currency has little direct impact on the world's largest nations, the domino effects of its monetary programs have many different wave lengths.

Japan's stock market jumped Monday after global finance leaders gave a seal of approval to the country's stimulus program and refrained from criticizing its weakening effect on the yen.

To counter these effects, the Obama Administration has rolled out programs incentivizing banks to reduce the amount owed on the mortgages of underwater homes.

online pharmacy thyroid medicine http://sildenafil-online.spruz.com/pt/Kamagra-generique/blog.htm#564 — link physiological effects of hyperbaric medicine us navy medicine http://sildenafil-online.spruz.com/pt/Kamagra-goedkoop/blog.htm#675 — kamagra goedkoop het emergency medicine physician payson arizona chinese medicine buy cupping http://sildenafil-online.spruz.com/pt/Kamagra-gold/blog.htm#676 — gold side effects kamagra tablets pro socialized medicine prescription medicine side - affects http://sildenafil-online.spruz.com/pt/Kamagra-gold-100/blog.htm#507 — kamagra gold 100 100 mg what pharmacy companies makes lorazepam medicines finder archive http://sildenafil-online.spruz.com/pt/Kamagra-groningen/blog.htm#547 — link closed head injury chinese medicine best on line pharmacy http://sildenafil-online.spruz.com/pt/Kamagra-holland/blog.htm#706 — holland kamagra oral jelly saba scool of medicine pharmacy technician duty http://sildenafil-online.spruz.com/pt/Kamagra-india/blog.htm#637 — buy kamagra from india jelly oral flea medicine pharmacy tech jobs wa kitsap http://sildenafil-online.spruz.com/pt/Kamagra-info/blog.htm#784 — link advil headache medicine man turns blue from medicine http://sildenafil-online.spruz.com/pt/Kamagra-ingredients/blog.htm#253 — ingredients buy kamagra antique doctor george family medicine cabinet ambulatory clinic pharmacy al < a href = http://sildenafil-online.spruz.com/pt/Kamagra-generique/blog.htm#614 — kamagra generique fadare yale school of medicine medicine chinoise reve songe < a href = http://sildenafil-online.spruz.com/pt/Kamagra-goedkoop/blog.htm#136 — link lydia e pinkham's medicine bottles wal - mart pharmacy website < a href = http://sildenafil-online.spruz.com/pt/Kamagra-gold/blog.htm#275 — kamagra gold generic naturopathic medicine integration free medicine volunteer programs in northwest indiana < a href = http://sildenafil-online.spruz.com/pt/Kamagra-gold-100/blog.htm#212 — kamagra gold 100 mg staywell pharmacy family medicine newton ks < a href = http://sildenafil-online.spruz.com/pt/Kamagra-groningen/blog.htm#659 — kamagra groningen approved where did sports medicine start compounding pharmacies north atlanta < a href = http://sildenafil-online.spruz.com/pt/Kamagra-holland/blog.htm#335 — link alternative complementary medicine statistics colorado pharmacy school tech < a href = http://sildenafil-online.spruz.com/pt/Kamagra-india/blog.htm#502 — kamagra oral jelly india walmart pharmacy branson west mo long's pharmacy las vegas < a href = http://sildenafil-online.spruz.com/pt/Kamagra-info/blog.htm#943 — kamagra gel info best sports medicine doctor in america pharmacy tech math < a href = http://sildenafil-online.spruz.com/pt/Kamagra-ingredients/blog.htm#599 — kamagra gel ingredients on - line pharmacy 90633